Truist raised the firm’s price target on Fresenius Medical (FMS) to $30 from $25 and keeps a Hold rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care (FMS) Discloses Q2 Dividend: What Shareholders Should Know
- Fresenius Medical Care Q1 2025 Earnings Call Highlights
- Fresenius Medical Care: Balanced Outlook with Hold Rating Amid Mixed Growth Signals
- Fresenius Medical Care Reports Strong Q1 2025 Earnings
- Fresenius Medical Care AG Announces Q1 2025 Financial Results and EUR 600 Million Note Issuance